Advertisement

Clinical Pharmacokinetics

, Volume 53, Issue 3, pp 205–212 | Cite as

Role of Microdialysis in Pharmacokinetics and Pharmacodynamics: Current Status and Future Directions

  • Francine Johansson Azeredo
  • Teresa Dalla Costa
  • Hartmut DerendorfEmail author
Review Article

Abstract

Diagnostic and therapeutic decisions in medical practice are still generally based on blood concentrations of drugs and/or biomolecules despite the knowledge that biochemical events and pharmacological effects usually take place in tissue rather than in the bloodstream. Microdialysis is a semi-invasive technique that is able to measure concentrations of the free, active drug or endogenous compounds in almost all human tissues and organs. It is currently being used to monitor brain metabolic processes and quantify tissue biomarkers, and determine transdermal drug distribution and tissue pharmacokinetics, confirming its importance as a widely used sampling technique in clinical drug monitoring and drug development as well as therapy and disease follow-up, contributing to rationalizing drug dosing regimens and influencing the clinical decision-making process.

Keywords

Minimum Inhibitory Concentration Deep Brain Stimulation Cerebral Spinal Fluid Microdialysis Probe Doripenem 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This manuscript was not supported by any grant. No founding sources were used in the preparation of this review and the authors have no conflicts of interest regarding the content of this review.

References

  1. 1.
    Ungerstedt U, Pycock C. Functional correlates of dopamine neurotransmission. Bull Schweiz Akad Med Wiss. 1974;30:44–55.PubMedGoogle Scholar
  2. 2.
    Plock N, Kloft C. Microdialysis—theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1–24.CrossRefGoogle Scholar
  3. 3.
    Muller M, De La Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48:1441–53.CrossRefGoogle Scholar
  4. 4.
    Johanssen MJ, Newman RA, Madden T. The use of microdialysis in pharmacokinetic and pharmacodynamic. Pharmacotherapy. 1997;17(3):464–81.Google Scholar
  5. 5.
    Chaurasia C, Müller M, Bashaw ED, et al. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol. 2007;47:589–603.CrossRefGoogle Scholar
  6. 6.
    Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. Antimicrob Chemother. 1993;31 Suppl. D:1–16.CrossRefGoogle Scholar
  7. 7.
    Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson’s disease. Mov Disord. 2005;20:1449–54.CrossRefGoogle Scholar
  8. 8.
    Hillered L, Vespa PM, Hovda DA. Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis. J Neurotrauma. 2005;22(1):3–41.CrossRefGoogle Scholar
  9. 9.
    Brunner M, Derendorf H. Clinical microdialysis: current applications and potential use in drug development. Trends Anal Chem. 2006;25(7):674–80.CrossRefGoogle Scholar
  10. 10.
    Joukhadar C, Mueller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet. 2005;44(9):895–913.CrossRefGoogle Scholar
  11. 11.
    Carrel T, Schmid ER, von Segesser L, et al. Perioperative assessment of the likelihood of infection of the lower respiratory tract after cardiac surgery. Thorac Cardiovasc Surg. 1991;39:85–8.CrossRefGoogle Scholar
  12. 12.
    Brunner M, Pernersdorfer T, Mayer B, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med. 2000;28:1754–9.CrossRefGoogle Scholar
  13. 13.
    Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med. 2001;29:385–91.CrossRefGoogle Scholar
  14. 14.
    Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamics surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143–60.CrossRefGoogle Scholar
  15. 15.
    Theuretzbacher U. Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses? Curr Opin Pharmacol. 2007;7:498–504.CrossRefGoogle Scholar
  16. 16.
    Mouton JW, Theuretzbacher U, Craig WA, et al. Tissue concentrations: do we ever learn? J Antimicrob Chemother. 2008;61:235–7.CrossRefGoogle Scholar
  17. 17.
    Traunmueller F, Zeitlinger M, Zeleny P, et al. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antmicrob Agents Chemother. 2007;519(9):3185–9.CrossRefGoogle Scholar
  18. 18.
    Hutschala D, Skhirtladze K, Kinstner C, et al. In vivo microdialysis to measure antibiotic penetration into soft tissue during cardiac surgery. Ann Thorac Surg. 2007;84:1605–10.CrossRefGoogle Scholar
  19. 19.
    Barbour A, Schmidt S, Rout RW, et al. Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents. 2009;34:231–5.CrossRefGoogle Scholar
  20. 20.
    Hutschala D, Kinstner C, Skhirtladze K, et al. The impact of perioperative atelectasis on antibiotic penetration into lung tissue: an in vivo microdialysis study. J Intensive Care Med. 2008;34:1827–34.CrossRefGoogle Scholar
  21. 21.
    Poeppl W, Zeitlinger M, Donath O, et al. Penetration of doripenem in human brain: an observational microdialysis study in patients with acute brain injury. Int J Antimicrob Agents. 2012;39:343–5.CrossRefGoogle Scholar
  22. 22.
    Schmidt S, Barbour A, Sahre M, et al. PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol. 2008;8:549–56.CrossRefGoogle Scholar
  23. 23.
    Jain RK. Delivery of molecular medicine to solid tumors. Science. 1996;271(5252):1079–80.CrossRefGoogle Scholar
  24. 24.
    Zamboni WC, Houghton PJ, Hulstein JL, et al. Interpatient variability in bioavailability and pharmacokinetics of oral topotecan in children with relapsed solid tumors. Cancer Chemother Pharmacol. 1999;43:269–76.CrossRefGoogle Scholar
  25. 25.
    Brunner M, Muller M. Microdialysis: an in vivo approach for measuring drug delivery in oncology. Eur J Clin Pharmacol. 2002;58(4):227–34.CrossRefGoogle Scholar
  26. 26.
    Konings IR, Engels FK, Sleijfer S, et al. Application of prolonged microdialysis sampling in carboplatin-treated cancer patients. Cancer Chemother Pharmacol. 2009;64:509–16.CrossRefGoogle Scholar
  27. 27.
    Konings IR, Sleijfer S, Mathijssen RH, et al. Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. Cancer Chemother Pharmacol. 2011;67(5):1055–62.CrossRefGoogle Scholar
  28. 28.
    Motl S, Zhuang Y, Waters CM, et al. Pharmacokinetic considerations in the treatment of CNS tumours. Clin Pharmacokinet. 2006;45:871–903.CrossRefGoogle Scholar
  29. 29.
    Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery, development. Nat Rev Drug Discov. 2007;6:650–61.CrossRefGoogle Scholar
  30. 30.
    Abbott N. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro, in silico models. Drug Discov Today Technol. 2004;1:407–16.CrossRefGoogle Scholar
  31. 31.
    Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295–305.CrossRefGoogle Scholar
  32. 32.
    Collins J, Dedrick R. Distributed model for drug delivery to CSF and brain tissue. Am J Physiol Regul Integr Comp Physiol. 1983;245(3):R303–10.CrossRefGoogle Scholar
  33. 33.
    de Lange E, Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet. 2002;41(10):691–703.CrossRefGoogle Scholar
  34. 34.
    Blakeley JO, Olson J, Grossman SA, et al. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study. J Neurooncol. 2009;91:51–8.CrossRefGoogle Scholar
  35. 35.
    Portnow J, Badie B, Chen M, et al. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implication for the current approach to chemoradiation. Clin Cancer Res. 2009;15:7092–8.CrossRefGoogle Scholar
  36. 36.
    Shah VP. Progress in methodologies for evaluating bioequivalence of topical formulations. Am J Clin Dermatol. 2001;2(5):275–80.CrossRefGoogle Scholar
  37. 37.
    Au WL, Skinner MF, Benfeldt E, et al. Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Skin Pharmacol Physiol. 2012;25:17–24.CrossRefGoogle Scholar
  38. 38.
    Ortiz PG, Hansen SH, Shah VP, et al. Are marketed topical metronidazole creams bioequivalent? Evaluation by in vivo microdialysis sampling and tape stripping methodology. Skin Pharmacol Physiol. 2011;24:44–53.CrossRefGoogle Scholar
  39. 39.
    Tettey-Amlalo RNO, Kanfer I, Skinner MF, et al. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci. 2009;36:219–25.CrossRefGoogle Scholar
  40. 40.
    Brunner M, Davies D, Martin W, et al. A new topical formulation enhances relative diclofenac bioavailability in healthy male subjects. Br J Clin Pharmacol. 2011;71(6):852–9.CrossRefGoogle Scholar
  41. 41.
    Simmel F, Kirbs C, Erdogan Z, et al. Pilot investigation on long-term subcutaneous microdialysis: proof of principle in humans. AAPS J. 2013;15(1):95–103.CrossRefGoogle Scholar
  42. 42.
    Ortiz PG, Hansen SH, Shah VP, et al. Impact of adult atopic dermatitis on topical drug penetration: assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89:33–8.CrossRefGoogle Scholar
  43. 43.
    Ortiz PG, Hansen SH, Shah VP, et al. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation investigated by microdialysis and dermatopharmacokinetic methods. Cont Derm. 2008;59(1):23–30.CrossRefGoogle Scholar
  44. 44.
    Lonnroth P, Jansson PA, Smith U. A microdialysis method allowing characterization of intercellular water space in humans. Am J Physiol. 1987;253(2 Pt 1):E228–31.PubMedGoogle Scholar
  45. 45.
    Blin O, Audebert C, Pitel S, et al. Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies. Psychopharmacology. 2009;207:201–12.CrossRefGoogle Scholar
  46. 46.
    Olivecrona M, Rodling-Wahlstrom M, Naredi S, et al. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009;26:1251–62.CrossRefGoogle Scholar
  47. 47.
    Brody DL, Magnoni S, Schwetye KE, et al. Amyloid-β dynamics correlate with neurological status in the injured human brain. Science. 2008;321(5893):1221–4.CrossRefGoogle Scholar
  48. 48.
    Zsigmond P, Dernroth N, Kullman A, et al. Stereotactic microdialysis of the basal ganglia in Parkinson’s disease. J Neurosci Methods. 2012;207:17–22.CrossRefGoogle Scholar
  49. 49.
    Feichtner F, Schaller R, Fercher A, et al. Microdialysis based device for continuous extravascular monitoring of blood glucose. Biomed Microdevices. 2010;12:399–407.CrossRefGoogle Scholar
  50. 50.
    Rooyackers O, Blixt C, Mattsson P, Wernerman J. Continuous glucose monitoring by intravenous microdialysis. Acta Anaesthesiol Scand. 2010;54(7):841–7.CrossRefGoogle Scholar
  51. 51.
    Helmark IC, Mikkelsen UR, Børglum J, et al. Exercise increases interleukin-10 levels in both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial. Arth Res Ther. 2010;12:R126–37.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Francine Johansson Azeredo
    • 1
  • Teresa Dalla Costa
    • 1
  • Hartmut Derendorf
    • 2
    Email author
  1. 1.Programa de Pós-Graduação em Ciências FarmacêuticasUFRGSPorto AlegreBrazil
  2. 2.Department of Pharmaceutics, College of PharmacyUniversity of FloridaGainesvilleUSA

Personalised recommendations